Request for Project Proposals: Production of Drug Substances and Drug Products at Commercial Scale – Anti-Microbials and Large Volume Parenterals

HHS DPA Title III Program is seeking to develop a drug substance and drug product manufacturing design-build-test cycle at a scale that demonstrates the ability to produce hundreds of millions of doses of drug substances to support the American public (population scale), with a focus of sustaining domestic production capacities. HHS DPA Title III Program is interested in submissions that address at least one (1) key starting material, drug substance, and/or drug product that support the production of the medicines cited within the broader FDA’s Essential Medicines List, with a preference for submissions that focus on Anti-Microbials and Large Volume Parenterals. The Program is particularly interested in those drug substances and key starting materials that do not currently have a domestic manufacturer, have fragile supply chains, are overly reliant on foreign suppliers, and/or are identified by the FDA as “currently in shortage”. 

See RPP Section 3.3 for Submission Details

Details

RPP Re-Opened and Amendment 2 Released: November 17, 2026

Changes: Updates the RPP and Attachment A. Submission deadline is extended to December 3, 2026 by 1 PM ET.

–

Amendment 1 Released: March 5, 2026

Changes: Extends the Enhanced White Paper due date to March 16, 2026 by 1 PM ET.

–

Q&A Posted: March 2, 2026

–

RPP Released: February 6, 2026